Dynavax Technologies Corp (Dynavax) is a biopharmaceutical company that discovers and develops novel vaccines and therapeutics. It harnesses the power of the human body’s innate and adaptive immune responses through toll-like receptor stimulation. The company works on modulation of endosomal TLRs, which is a family of transmembrane proteins that play a role in innate immunity and subsequent adaptive immunity.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Dynavax R&D to advance its pipeline candidates for the treatment of hepatitis B, melanoma, head and neck squamous cell carcinoma, liver cancer, and multiple malignancies. - In FY2022, Dynavx incurred R&D expenses of US$46.6 million. - As of December 2022, the company's intellectual property portfolio comprised more than 25 issued US patents, over 60 issued foreign patents and more than 22 pending US and foreign patent applications.